A randomized single-blind trial of the therapeutic effects and safety of halved dose antipsychotics for treating relapse in patients with schizophrenia receiving high dose antipsychotic therapy
Not Applicable
- Conditions
- schizophrenia
- Registration Number
- JPRN-UMIN000047785
- Lead Sponsor
- Showa University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 54
Inclusion Criteria
Not provided
Exclusion Criteria
intellectual disability, neurodevelopmental disorders, organic, including symptomatic, mental disorder, long term depot antipsychotics within 3 months, electroconvulsive therapy within 6 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the period from occurrence of relapse until relapse symptom improvement
- Secondary Outcome Measures
Name Time Method Psychiatric symptoms will be evaluated according to the Positive and Negative Syndrome Scale (PANSS), and extrapyramidal symptoms (EPS) according to the Drug-induced Extra-pyramidal Symptoms Scale (DIEPSS) at baseline, at relapse, and after remission. All adverse events that appear will be evaluated.